| |
Company
Roster
|
|
Total
Insiders : |
39 |
|
|
|
Total
Direct Shares :
|
16,928,073 |
|
|
Total
Indirect Shares :
|
16,792,297 |
| |
%
Held by Insiders:
|
16.17% |
|
|
| |
| Filer's Name |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
  Thompson Craig B. |
Director |
2025-01-02 |
620 |
2022-10-03 |
0 |
| Goldstein Joseph L |
Director |
2025-01-02 |
6,548 |
2003-10-08 |
0 |
| Coles N Anthony |
Director |
2025-01-02 |
1,559 |
2019-01-02 |
0 |
| Poon Christine A |
Director |
2025-01-02 |
2,352 |
2014-05-21 |
0 |
| Guarini Kathryn |
Director |
2025-01-02 |
448 |
2023-09-08 |
0 |
| Ryan Arthur F |
Director |
2025-01-02 |
17,748 |
2010-06-14 |
0 |
| Bassler Bonnie L |
Director |
2025-01-02 |
1,548 |
2019-01-02 |
0 |
| Schenkein David P |
Director |
2025-01-02 |
448 |
2023-09-08 |
0 |
| Zoghbi Huda Y |
Director |
2025-01-02 |
1,548 |
2019-01-02 |
0 |
| Brown Michael S |
Director |
2025-01-02 |
1,548 |
2025-01-02 |
11,162 |
| Sing George L |
Director |
2025-01-02 |
27,828 |
2025-01-02 |
2,150 |
| Pitofsky Jason |
VP Controller |
2024-12-16 |
4,664 |
2024-12-16 |
190 |
| Van Plew Daniel P |
EVP & General Mgr, Industrial |
2024-12-16 |
34,792 |
2024-12-16 |
1,100 |
| Murphy Andrew J |
EVP Research |
2024-12-16 |
49,074 |
2024-12-16 |
4,326 |
| Larosa Joseph J |
EVP General Counsel and Secret |
2024-12-16 |
30,075 |
2024-12-16 |
9,371 |
| Mccourt Marion |
EVP Commercial |
2024-12-16 |
14,230 |
2024-12-16 |
174 |
| Fenimore Christopher R. |
SVP Finance & CFO |
2024-12-16 |
16,265 |
2024-12-16 |
3,462 |
| Stahl Neil |
EVP Research and Development |
2024-12-16 |
48,829 |
2024-12-16 |
10,454 |
| Schleifer Leonard S |
Bd. Co-Chair, President & CEO, Director |
2024-06-12 |
466,877 |
2024-06-12 |
163,484 |
| Yancopoulos George |
Bd. Co-Chair, President & CSO, Director |
2024-06-10 |
868,994 |
2024-06-10 |
241,951 |
| Landry Robert E |
EVP Finance CFO |
2024-02-02 |
23,693 |
2024-02-02 |
270 |
| Vagelos P Roy |
Director |
2023-04-03 |
312,578 |
2023-04-03 |
154,526 |
| Tessier-Lavigne Marc |
Director |
2023-01-03 |
2,434 |
2013-05-06 |
0 |
| Sanofi-Aventis |
|
2020-05-29 |
0 |
2020-06-09 |
279,766 |
| Baker Charles A |
Director |
2017-09-29 |
9,000 |
2013-11-26 |
0 |
| Terifay Robert J |
EVP Commercial |
2017-08-10 |
25,214 |
2017-08-10 |
1,699 |
| Aberman Michael S |
SVP Strategy Investor Relation |
2017-06-22 |
4,693 |
2017-06-22 |
12,253 |
| Powchik Peter |
SVP Clinical Development & Reg |
2016-05-16 |
25,714 |
2016-05-16 |
4,133 |
| Mccorkle Douglas S |
VP Controller and Asst Treasur |
2015-12-29 |
6,866 |
2015-12-29 |
4,129 |
| Gilman Alfred G |
Director |
2015-08-06 |
8,912 |
2003-09-11 |
0 |
| Ingram Robert Alexander |
Director |
2015-05-27 |
1,500 |
2015-05-22 |
0 |
| Goldberg Murray A |
SVP Administration & Asst Secr |
2014-12-16 |
64,436 |
2014-12-16 |
6,400 |
| Shooter Eric M |
Director |
2014-02-12 |
0 |
2014-02-12 |
5,000 |
| Roberts William |
VP Reg Dev & Med Safety |
2013-10-02 |
16,644 |
2013-10-02 |
55,634 |
| Kolinski Stuart |
SVP General Counsel and Secret |
2010-06-03 |
16,329 |
2010-06-03 |
3,710 |
| Sanofi-Aventis Amerique Du Nord S.n.c. |
10% Owner |
2007-12-20 |
14,799,552 |
2010-10-13 |
15,816,953 |
| Rupp Randall |
SVP, Manufuring Operations |
2007-04-13 |
3,983 |
2003-09-15 |
0 |
| Novartis Pharma Ag |
10% Owner |
2005-11-08 |
0 |
2005-11-08 |
0 |
| Guler Hans Peter |
VP Clinical Programs |
2004-10-08 |
10,530 |
2003-12-15 |
0 |
|
1.98 (0.38%) 
